open access

Vol 81, No 2 (2010)
ARTICLES
Get Citation

Influence of pharmacological treatment on selected parameters of intrahepatic cholestasis of pregnancy

Maria Brzozowska, Urszula Kowalska-Koprek, Agata Karowicz-Bilińska
Ginekol Pol 2010;81(2).

open access

Vol 81, No 2 (2010)
ARTICLES

Abstract

Summary Intrahepatic cholestasis occurs most frequently in the third trimester of pregnancy. It is characterized by elevated concentrations of liver enzymes and bile acids. The main aim of the study was to analyze the changes of concentration in biochemical indicators of cholestasis during the treatment. Material and methods: The study was conducted in the group of 38 women with diagnosed intrahepatic cholestasis in pregnancy and hospitalized in Medical University Lodz, High Risk Pregnancy Clinic in 2007-2008. Treatment constituted UDCA in 750mg per 24h and Essentiale Forte 3 times a day. The concentrations in serum of AspAt, AlAt, ALP, GGTP, bile acids and bilirubin were estimated before and after 7 and 15 days of the treatment. Results: Mean concentration of AlAt was 262±16.26 U/L, AspAt 146±141.17 U/L, ALP 189±60.64 U/L, bile acids 28.6±15μmol/L, GGTP 31.5±28.15U/L but only in 28,9%was elevated. After 7 days the decrease of mean concentrations of AlAt (165±126.7 U/L) and AspAt (85±59.62 U/L) was observed. The concentration of ALP was similar to the previous results (190±71.94 U/L). After 15 days mean values of AlAt and AspAt decreased to 119±103.56 U/L and 65±46.12 U/L (p<0.001), No changes in ALP concentration were found. The concentration of bile acids decreased after 15 days to17±15μmol/L. Conclusions: The applied treatment decreased the concentration of most of biochemical markers of cholestasis. To reach the normal values of concentration of biochemical markers of cholestasis a 15-day treatment is necessary.

Abstract

Summary Intrahepatic cholestasis occurs most frequently in the third trimester of pregnancy. It is characterized by elevated concentrations of liver enzymes and bile acids. The main aim of the study was to analyze the changes of concentration in biochemical indicators of cholestasis during the treatment. Material and methods: The study was conducted in the group of 38 women with diagnosed intrahepatic cholestasis in pregnancy and hospitalized in Medical University Lodz, High Risk Pregnancy Clinic in 2007-2008. Treatment constituted UDCA in 750mg per 24h and Essentiale Forte 3 times a day. The concentrations in serum of AspAt, AlAt, ALP, GGTP, bile acids and bilirubin were estimated before and after 7 and 15 days of the treatment. Results: Mean concentration of AlAt was 262±16.26 U/L, AspAt 146±141.17 U/L, ALP 189±60.64 U/L, bile acids 28.6±15μmol/L, GGTP 31.5±28.15U/L but only in 28,9%was elevated. After 7 days the decrease of mean concentrations of AlAt (165±126.7 U/L) and AspAt (85±59.62 U/L) was observed. The concentration of ALP was similar to the previous results (190±71.94 U/L). After 15 days mean values of AlAt and AspAt decreased to 119±103.56 U/L and 65±46.12 U/L (p<0.001), No changes in ALP concentration were found. The concentration of bile acids decreased after 15 days to17±15μmol/L. Conclusions: The applied treatment decreased the concentration of most of biochemical markers of cholestasis. To reach the normal values of concentration of biochemical markers of cholestasis a 15-day treatment is necessary.
Get Citation

Keywords

Cholestasis, pregnancy, treatment, Ursodeoxycholic Acid

About this article
Title

Influence of pharmacological treatment on selected parameters of intrahepatic cholestasis of pregnancy

Journal

Ginekologia Polska

Issue

Vol 81, No 2 (2010)

Bibliographic record

Ginekol Pol 2010;81(2).

Keywords

Cholestasis
pregnancy
treatment
Ursodeoxycholic Acid

Authors

Maria Brzozowska
Urszula Kowalska-Koprek
Agata Karowicz-Bilińska

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl